Q3 2023 Results - Reimagining Medicine
Existing brands
Company overview
Innovation: Pipeline overview
Financial review
Financial performance
Novartis submission schedule
Supplementary indications for existing brands
Conclusions
Appendix
Innovation: Clinical trials
References
Abbreviations
INNOVATION
Cardiovascular
Immunology
Neuroscience
Oncology
Non-core TA project
Kisqali®
2023
ribociclib, LEE011
HR+/HER2- BC (adj)
XolairⓇ
omalizumab, IGE025
Food allergy
JakaviⓇ
2024
ruxolitinib, INC424
Pediatrics Acute GVHD
JakaviⓇ
ruxolitinib, INC424
Pediatrics Chronic GVHD
LutatheraⓇ
177Lu-oxodotreotide¹
GEP-NET 1L G3
ScemblixⓇ
ABL001
CML 1L
Adakveo
SEG101
Sickle cell disease, pediatrics
Coartem®
artemether+lumefantrine, COA566
Malaria uncompl., formula for <5kg
2025
Cosentyx®
secukinumab, AIN457
GCA
Leqvio®
KJX839
Ped Hyperlipidemia
ZolgensmaⓇ
AVXS-101 OAV101
SMA IT
BeovuⓇ
brolucizumab, RTH258
Diabetic retinopathy
PromactaⓇ
eltrombopag, ETB115
Radiation sickness syndrome
AimovigⓇ
erenumab, AMG334
Pediatric Migraine
Cosentyx®
secukinumab, AIN457
Tendinopathy
CosentyxⓇ
secukinumab, AIN457
Polymyalgia rheumatica
AtecturaⓇ
indacaterol + mometasone, QMF149
Asthma, pediatrics
KesimptaⓇ 2
ofatumumab
Multiple sclerosis, pediatrics
LeqvioⓇ
KJX839
CVRR-LDLC
1. 177 Lu-dotatate in US. 2. Kesimpta and Mayzent: Pediatric trial in multiple sclerosis run in conjunction (NEOS).
39 Investor Relations | Q3 2023 Results
≥2026
LeqvioⓇ
KJX839
Primary prevention
MayzentⓇ 2
siponimod, BAF312
Multiple sclerosis, pediatrics
RydaptⓇ
midostaurin, PKC412
Acute myeloid leukemia, pediatrics
ScemblixⓇ
ABL001
CML, 2L, pediatrics
NOVARTIS | Reimagining Medicine
OView entire presentation